PTK2 and ovarian cancer: - Inhibits migration and tube formation of endothelial cells (HUVECs) and ovarian cancer cells (SKOV3) without altering macrophage polarization.- Shows anti-angiogenic properties by inhibiting FAK phosphorylation in cancer and endothelial cells.- Potential for repositioning as an anticancer drug in invasive cancers due to selective effects on cancer and TME.